<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; for</title>
	<atom:link href="http://www.tapanray.in/tag/for/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Public Healthcare Space: Evaluating Three Fresh Edicts</title>
		<link>http://www.tapanray.in/public-healthcare-space-evaluating-three-fresh-edicts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=public-healthcare-space-evaluating-three-fresh-edicts</link>
		<comments>http://www.tapanray.in/public-healthcare-space-evaluating-three-fresh-edicts/#comments</comments>
		<pubDate>Mon, 02 Dec 2013 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2010]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[edicts]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Establishment Act]]></category>
		<category><![CDATA[Establishments]]></category>
		<category><![CDATA[evaluating]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[laudative]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NCCE]]></category>
		<category><![CDATA[off]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ready]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[steps]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[take]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[welcoming]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4307</guid>
		<description><![CDATA[Medicines constitute a significant cost component of modern healthcare systems across the world. However, in India the situation is even worse, where as per recent studies, drugs contribute as high as around 70 percent of the total treatment cost. This &#8230; <a href="http://www.tapanray.in/public-healthcare-space-evaluating-three-fresh-edicts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/public-healthcare-space-evaluating-three-fresh-edicts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Concept of Orphan Drugs for Orphan Diseases is Orphan in India</title>
		<link>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india</link>
		<comments>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/#comments</comments>
		<pubDate>Mon, 10 Sep 2012 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Concept]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=36</guid>
		<description><![CDATA[Though the percentage of patients suffering from ‘Rare Diseases’ in India is reportedly higher than the  world average, unfortunately even today such cases get little help from our government. According to experts, diseases manifesting patients representing maximum 6 to 8 &#8230; <a href="http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The ruckus over Clinical Trials in India compels Government tightening regulations before flooring gas pedal for regional leadership</title>
		<link>http://www.tapanray.in/the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership</link>
		<comments>http://www.tapanray.in/the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership/#comments</comments>
		<pubDate>Mon, 13 Aug 2012 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[before]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[compels]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[flooring]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[gas]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pedal]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[regional]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[ruckus]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[tightening]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=52</guid>
		<description><![CDATA[The subject of Clinical Trials in India has created a huge ruckus, mainly for wide spread alleged malpractices, abuse and misuse of the fragile regulations of the country by the players in this field. The issue is not just of &#8230; <a href="http://www.tapanray.in/the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Free Essential Medicines for All’ &#8211; A Laudable Public Healthcare Initiative of India, Tough Challenges Notwithstanding</title>
		<link>http://www.tapanray.in/free-essential-medicines-for-all-a-laudable-public-healthcare-initiative-of-india-tough-challenges-notwithstanding/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=free-essential-medicines-for-all-a-laudable-public-healthcare-initiative-of-india-tough-challenges-notwithstanding</link>
		<comments>http://www.tapanray.in/free-essential-medicines-for-all-a-laudable-public-healthcare-initiative-of-india-tough-challenges-notwithstanding/#comments</comments>
		<pubDate>Mon, 16 Jul 2012 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[Laudable]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Notwithstanding]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tough]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=66</guid>
		<description><![CDATA[Recently the Government of India has taken a landmark ‘Public Healthcare’ related initiative to provide unbranded generic formulations of all essential drugs, featuring in the ‘National List of Essential Medicines 2011’, free of cost to all patients from the public &#8230; <a href="http://www.tapanray.in/free-essential-medicines-for-all-a-laudable-public-healthcare-initiative-of-india-tough-challenges-notwithstanding/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/free-essential-medicines-for-all-a-laudable-public-healthcare-initiative-of-india-tough-challenges-notwithstanding/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Chasing the “Holy Grail”: Reasonably affordable healthcare for all</title>
		<link>http://www.tapanray.in/chasing-the-holy-grail-reasonably-affordable-healthcare-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=chasing-the-holy-grail-reasonably-affordable-healthcare-for-all</link>
		<comments>http://www.tapanray.in/chasing-the-holy-grail-reasonably-affordable-healthcare-for-all/#comments</comments>
		<pubDate>Mon, 23 Apr 2012 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[Chasing]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Grail]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Holy]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reasonably]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=103</guid>
		<description><![CDATA[The Healthcare industry of the world as a whole with a size of several trillion US$ is growing at a fast pace in many countries for various reasons. The industry can be broadly divided into six categories as follows: Managed &#8230; <a href="http://www.tapanray.in/chasing-the-holy-grail-reasonably-affordable-healthcare-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/chasing-the-holy-grail-reasonably-affordable-healthcare-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Grant of Compulsory License for Bayer’s Nexavar in India raises more questions than answers</title>
		<link>http://www.tapanray.in/grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers</link>
		<comments>http://www.tapanray.in/grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers/#comments</comments>
		<pubDate>Mon, 26 Mar 2012 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[answers]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CGPDTM]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[controller]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[questions]]></category>
		<category><![CDATA[raises]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[than]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=116</guid>
		<description><![CDATA[On March 12, 2012, the Patent Office of India, in its landmark ruling, granted its first ever Compulsory License (CL) for Bayer’s patented kidney and liver cancer drug Nexavar (Sorafenib), to the generic pharma player Natco, broadly citing the following &#8230; <a href="http://www.tapanray.in/grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Arresting continuous job losses in the global pharma industry call for innovation across the value chain</title>
		<link>http://www.tapanray.in/arresting-continuous-job-losses-in-the-global-pharma-industry-call-for-innovation-across-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=arresting-continuous-job-losses-in-the-global-pharma-industry-call-for-innovation-across-the-value-chain</link>
		<comments>http://www.tapanray.in/arresting-continuous-job-losses-in-the-global-pharma-industry-call-for-innovation-across-the-value-chain/#comments</comments>
		<pubDate>Mon, 05 Mar 2012 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Across]]></category>
		<category><![CDATA[Arresting]]></category>
		<category><![CDATA[call]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[continuous]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[losses]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=125</guid>
		<description><![CDATA[In not too distant past, the stocks of the global pharmaceutical companies, by and large, used to be categorized as ‘blue-chips’ for their high return to investors, as compared to many other sectors. Unfortunately, the situation has changed significantly since &#8230; <a href="http://www.tapanray.in/arresting-continuous-job-losses-in-the-global-pharma-industry-call-for-innovation-across-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/arresting-continuous-job-losses-in-the-global-pharma-industry-call-for-innovation-across-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quantum Growth Envisaged in Government Procurement for Pharmaceuticals: A Challenging Ball Game for Pharma Players</title>
		<link>http://www.tapanray.in/quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players</link>
		<comments>http://www.tapanray.in/quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players/#comments</comments>
		<pubDate>Mon, 27 Feb 2012 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[ball]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[Envisaged]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Quantum]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=128</guid>
		<description><![CDATA[Direct procurement by the Governments of various countries is attracting increasing importance not just at the domestic level, but internationally, as well. The systems adopted for Government Procurement (GP) globally are aimed at making a significant difference in the effectiveness &#8230; <a href="http://www.tapanray.in/quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quantum-growth-envisaged-in-government-procurement-for-pharmaceuticals-a-challenging-ball-game-for-pharma-players/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Getting unfolded a global opportunity for India with Biosimilar Drugs</title>
		<link>http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 19 Dec 2011 00:20:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Getting]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[unfolded]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=159</guid>
		<description><![CDATA[Over a period of time, the trend of a disease treatment process is becoming more targeted and personalized to improve effectiveness of both diagnosis and treatment. Biotechnology being the key driver to this trend, India should not fall out of &#8230; <a href="http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/getting-unfolded-a-global-opportunity-for-india-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Health being a basic human right, the proposal for ‘Universal Health Coverage’ augurs well for India</title>
		<link>http://www.tapanray.in/health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india</link>
		<comments>http://www.tapanray.in/health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india/#comments</comments>
		<pubDate>Mon, 12 Dec 2011 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[augurs]]></category>
		<category><![CDATA[basic]]></category>
		<category><![CDATA[Being]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[well]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=162</guid>
		<description><![CDATA[“The right to health is relevant to all States: every State has ratified at least one international human rights treaty recognizing the right to health. Moreover, States have committed themselves to protecting this right through international declarations, domestic legislation and &#8230; <a href="http://www.tapanray.in/health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/health-being-a-basic-human-right-the-proposal-for-universal-health-coverage-augurs-well-for-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
